Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jaillon

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
The Journal of Antimicrobial Chemotherapy|April 1, 1989
Pharmacokinetics of amoxycillin/clavulanic acid in serum and ascitic fluid in cirrhotic patientsJ D Grange, A Gouyette, L Gutmann, et al.
European Journal of Clinical Pharmacology|April 11, 2001
Is diclofenac a valuable CYP2C9 probe in humans?S Morin, M A Loriot, J M Poirier, et al.
European Journal of Clinical Pharmacology|March 14, 2003
Genetic and environmental risk factors for oral anticoagulant overdoseC Verstuyft, A Robert, S Morin, et al.
Clinical Pharmacology and Therapeutics|March 1, 1990
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patientsA Rames, J M Poirier, F LeCoz, et al.
Journal of Cardiovascular Pharmacology|October 1, 1988
Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administrationB Lecocq, P Jaillon, V Lecocq, et al.
Annales De Biologie Clinique|June 14, 2003
[A new, rapid and robust genotyping method for CYP2C9 and MDR1]C Verstuyft, S Morin, J Yang, et al.
Clinical Pharmacology and Therapeutics|August 1, 1989
Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patientsP Jaillon, M E Gardin, B Lecocq, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2000
Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort InvestigatorsP M Girard, M Guiguet, D Bollens, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|December 1, 1989
[Electrophysiologic effects of intravenous 3-hydroxy-dihydroquinidine (LNC-834) in man]J Weissenburger, J Y le Heuzey, J Clementy, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|October 1, 1985
[Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole]P Dumoulin, P Jaillon, A Kher, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
The Journal of Antimicrobial Chemotherapy|April 1, 1989
Pharmacokinetics of amoxycillin/clavulanic acid in serum and ascitic fluid in cirrhotic patientsJ D Grange, A Gouyette, L Gutmann, et al.
European Journal of Clinical Pharmacology|April 11, 2001
Is diclofenac a valuable CYP2C9 probe in humans?S Morin, M A Loriot, J M Poirier, et al.
European Journal of Clinical Pharmacology|March 14, 2003
Genetic and environmental risk factors for oral anticoagulant overdoseC Verstuyft, A Robert, S Morin, et al.
Clinical Pharmacology and Therapeutics|March 1, 1990
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patientsA Rames, J M Poirier, F LeCoz, et al.
Journal of Cardiovascular Pharmacology|October 1, 1988
Clinical pharmacology of hydroxy-3(S)-dihydroquinidine in healthy volunteers following oral administrationB Lecocq, P Jaillon, V Lecocq, et al.
Annales De Biologie Clinique|June 14, 2003
[A new, rapid and robust genotyping method for CYP2C9 and MDR1]C Verstuyft, S Morin, J Yang, et al.
Clinical Pharmacology and Therapeutics|August 1, 1989
Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patientsP Jaillon, M E Gardin, B Lecocq, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2000
Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort InvestigatorsP M Girard, M Guiguet, D Bollens, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|December 1, 1989
[Electrophysiologic effects of intravenous 3-hydroxy-dihydroquinidine (LNC-834) in man]J Weissenburger, J Y le Heuzey, J Clementy, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|October 1, 1985
[Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole]P Dumoulin, P Jaillon, A Kher, et al.
Pageof 20